Jefferies has flagged four near-term catalysts in GSK PLC's (LSE:GSK, NYSE:GSK) oncology pipeline following a fireside chat with the pharmaceutical company's global head of oncology and research and development at the bank's New York healthcare conference, reiterating its buy rating and 2,500p price target on the stock. GSK, which is trading at 1,872p, plans to present additional datasets for its B7H3 antibody-drug conjugate.